#ASH25: Our collaborator María-Victoria Mateos will share results of a phase 3 study of teclistamab plus daratumumab for relapsed refractory #multiplemyeloma. #mmsm @mskcancercenter.bsky.social @ash.hematology.org @szusmani.bsky.social
TODAY | 8:45 a.m. EST
Learn more: bit.ly/3MN6MKr
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm
🗓️ Friday, September 19 | 9:40 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social
At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm
🗓️ Saturday, September 20 | 9:20 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm
🗓️ Wednesday, September 17 | 11:10 a.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma.
🗓️ Wednesday, September 17 | 12:14 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
Sign up to read exclusive expert insights on key abstracts to watch at #IMS25! @szusmani.bsky.social @mskcancercenter.bsky.social @myeloma-society.bsky.social #mmsm
www.onclive.com/view/experts...
Join Dr. @szusmani.bsky.social as he presents research on "Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed #MM (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study" at #ASCO25. @ascocancer.bsky.social
"The phase 3 CEPHEUS trial previously demonstrated improved efficacy outcomes with DVRd vs VRd in patients with TIE or transplant-differed NDMM," shares myeloma specialist
@szusmani.bsky.social during his session at #ASCO25.
@ascocancer.bsky.social
D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma @ascocancer.bsky.social @mskcancercenter.bsky.social @szusmani.bsky.social #ASCO25 #mmsm www.onclive.com/view/d-vrd-r...
Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and
@szusmani.bsky.social on being inducted into the 13th Giants of Cancer Care® class by @onclive.bsky.social! This award honors leading physicians who are advancing #cancerresearch. @mskcancercenter.bsky.social
Learn more: bit.ly/42Ox58M
❤️ Thank you, Dr. Usmani for continuing to support #MyelomaICE!
Dear all, putting in a plug for the International Myeloma Foundation Iceland Cycling Expedition 2025 below. Thanks for your generosity last year, many of you contributed to its success. Every donation and any amount counts.
@imfmyeloma.bsky.social
fundraise.myeloma.org/fundraiser/5...
1/ 🚨New research alert! 🚨Our study in Blood Cancer shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma, with @joedeasy.bsky.social, @malinhultcrantz.bsky.social, @szusmani.bsky.social, and the rest of the @mskcancercenter.bsky.social team! 🧵👇#MyelomaSky
NEW in @natmedicine.bsky.social: Results from a phase 3 clinical trial led by MSK's #myeloma specialist & cellular therapist @szusmani.bsky.social. Learn more: www.nature.com/articles/s41...
Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky
@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social
www.nature.com/articles/s41...
Thanks to @szusmani.bsky.social for donating 🙌🏾🙌🏾🙌🏾🥳🥳🥳 to support multiple myeloma cancer research @ give.themmrf.org/fundraiser/5...
This is your last chance to see incredible research at the #ASH24 poster session today! Don't miss posters by Drs. Gunjan Shah, Carlyn Rose Tan, & Pallawi Torka. @mskcancercenter.bsky.social @szusmani.bsky.social
6-8 p.m. PST
https://buff.ly/3ZLbSey
https://buff.ly/3OOjjeG
https://buff.ly/3Vum0Wv
Congratulations to MSK's Dr. Urvi Shah for being awarded the @ash-hematology.bsky.social David M. Goldenberg Clinical Research Training Institute Award for her work on research that shows that a high-fiber, plant-based dietary intervention may delay progression #MGUS/#SMM to #MM.
#ASH24 #ASHKudos
Dr. @szusmani.bsky.social presents on “Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept” that is part of the ASH Research Collaborative Multiple Myeloma Network at @ash-hematology.bsky.social.
#ASH24
Please join us now #ASH24
#MyelomaSky
ASH RESEARCH COLLABORATIVE MULTIPLE MYELOMA NETWORK: ACCELERATING RESEARCH AND COLLABORATIVE CLINICAL CARE THROUGH REAL-WORLD EVIDENCE GENERATION
December 7, 2024, 4:00 p.m. - 5:30 p.m.
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26
#ASH24: Join myeloma specialist Dr. @szusmani.bsky.social for his presentation on "Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept" today at 4pm PT at @ash-hematology.bsky.social.
bit.ly/49vscmW
Join Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease."
2:15 pm PST. #ASH24 @mskcancercenter.bsky.social
@szusmani.bsky.social @ash-hematology.bsky.social
buff.ly/4f6J3gP
☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern.
Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post!
🛑Remember, there's only one H in #ASHaiku!
#HemeSky #Hematology
592 Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
ash.confex.com/ash/2024/web...
766 Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
ash.confex.com/ash/2024/web...
672 Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
ash.confex.com/ash/2024/web...
591 NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
ash.confex.com/ash/2024/web...
251 DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
ash.confex.com/ash/2024/web...
